Loading...
By Kelly Young
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
Here are some of the recent developments on COVID-19:
New variant in U.S.: A more contagious variant of SARS-CoV-2 originally detected in the U.K. has been found in at least three U.S. states — Colorado, California, and Florida. CDC officials said the mutation was not expected to affect vaccine efficacy.
Half doses of vaccine? The government's coronavirus vaccine team is in discussions with Moderna and the FDA about whether to allow people to receive two doses of that vaccine at half the strength, Moncef Slaoui, the chief science adviser for Operation Warp Speed, said on CBS News' Face the Nation on Sunday. This could allow more people to receive the vaccine. In a clinical trial, participants aged 18 to 55 who received two 50-µg doses had a similar immune response as those who received two 100-µg doses. Two doses of the 100-µg mRNA-1273 vaccine had 94% efficacy against COVID-19, according to results of the phase 3 trial recently published in the New England Journal of Medicinee.
Antigen test sensitivity: Symptomatic people who have negative results from SARS-CoV-2 antigen tests should consider getting confirmation with a PCR test, as should asymptomatic people who have a positive antigen test, according to MMWR. Researchers studied antigen and PCR samples from over 1100 people presenting for COVID-19 testing. Among symptomatic people, the Sofia antigen test had a sensitivity of 80%, a specificity of 99%, a positive predictive value (PPV) of 94%, and a negative predictive value (NPV) of 96%. Among those without symptoms, the test had a sensitivity of 41%, a specificity of 98%, a PPV of 33%, and an NPV of 99%.
Comment
LINK(S):
CDC briefing transcript (Free)
CBS News' Face the Nation interview with Moncef Slaoui (Free)
FDA briefing document on Moderna's mRNA-1273 vaccine (Free)
NEJM article on mRNA-1273 vaccine (Free)
MMWR article on antigen test sensitivity (Free)
NEJM Journal Watch COVID-19 page (Free)
NEJM COVID-19 page (Free)